METHOD FOR PREDICTING PREMATURE AGING IN YOUNG AND MIDDLE-AGED MEN ASSOCIATED WITH POLYMORBID CARDIOVASCULAR PATHOLOGY Russian patent published in 2023 - IPC G01N33/68 G01N33/74 G01N33/573 

FIELD: medicine; gerontology.

SUBSTANCE: invention can be used to predict premature aging (PS) in young and middle-aged men associated with polymorbid cardiovascular pathology. The fibroblast growth factor value is assessed. The concentration of fibroblast growth factor 21 in blood serum is determined by enzyme immunoassay in ng/l, then the concentration of p53 protein in blood serum is determined by enzyme-linked immunosorbent assay in U/ml; then a determination of the concentration of CRP in the blood serum in mg/l is produced; then the concentration is determined β-endorphin in blood serum by enzyme immunoassay in ng/ml; then, the concentration of 6-SOMT day and 6-SOMT night in the urine is determined by enzyme immunoassay in ng/ml. Daily urine is collected not later than the third day from the time of hospitalization, and the samples collected from 11.00 p.m. to 7.00 a.m. are taken as one, the total volume of urine in the samples is measured, the urine is shaken and 5.0 ml is taken from the middle of the container into an Eppendorf-type test tube. All nightly sampling is carried out with illumination of no more than 30 lux, and patients are preliminarily adapted to the sleep/wake pattern — waking up at 07.00 a.m., falling asleep at 11.00 p.m., and prior to hospitalization, patients are excluded from the diet of foods rich in L-tryptophan. The average sleep duration of patients in groups is at least 7 hours. In the preanalytical period, urine tubes are centrifuged at 1,500 rpm for 15 minutes. Samples are then frozen and stored at -80°C up to the time of analysis. Then, each marker is encoded according to the formula z=ay+b, where y is the value of a particular marker in units of measurement, z is its potential code in relative units, a and b are coefficients, the values of which are taken from Table 4. Then, a private function d_i is calculated for each of the six markers according to the formula: d_i =exp(-exp(-z)), where d_i is a private function for the i-th marker, z is a potential code in relative units i-th marker. Then, the PS probability is calculated using the generalized Harrington function for all six markers according to the formula: , where d_1-6 is a private function of each marker, D is the probability of PS. If the value of the function is less than or equal to 0.2, an unlikely risk of developing body PS in young and middle-aged men is predicted according to the line of markers. When the value of the function is from 0.2 to 0.37 inclusive, a low risk of developing body PS in young and middle-aged men is predicted according to the line of markers. If the value of the function is from 0.37 to 0.63 inclusive, the average risk of developing PS of the organism in young and middle-aged men is predicted according to the line of markers. If the value of the function is from 0.63 to 0.8 inclusive, a high risk of developing body PS in young and middle-aged men is predicted according to the line of markers.

EFFECT: method provides the possibility of more informative and accurate prediction of PS in young and middle-aged men associated with polymorbid cardiovascular pathology, by taking into account such additional parameters as the concentration of p53 protein, CRP, β-endorphin in blood serum and the concentration of day and night fractions of 6-SOMT.

1 cl, 1 dwg, 4 tbl, 4 ex